Pettus, Jeremy H <br/><br/>
Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study.  [electronic resource] 

 -  Diabetes care  01 2020 
 - 161-168 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1935-5548 
<br/><br/><label>Standard No.: </label>10.2337/dc19-1328  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Alkanesulfonates--administration & dosage<br/>Benzamides--administration & dosage<br/>Blood Glucose--drug effects<br/>Diabetes Mellitus, Type 2--drug therapy<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Resistance--drug effects<br/>Drug Therapy, Combination<br/>Female<br/>Humans<br/>Hypoglycemic Agents--administration & dosage<br/>Male<br/>Metformin--therapeutic use<br/>Middle Aged<br/>Receptors, Glucagon--antagonists & inhibitors<br/>Treatment Outcome<br/>Young Adult